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X-linked adrenoleukodystrophy (X-ALD) is an inherited disorder characterized by axonopathy and demyelin-
ation in the central nervous system and adrenal insufﬁciency. Main X-ALD phenotypes are: (i) an adult adre-
nomyeloneuropathy (AMN) with axonopathy in spinal cords, (ii) cerebral AMN with brain demyelination
(cAMN) and (iii) a childhood variant, cALD, characterized by severe cerebral demyelination. Loss of function
of the ABCD1 peroxisomal fatty acid transporter and subsequent accumulation of very-long-chain fatty acids
(VLCFAs) are the common culprits to all forms of X-ALD, an aberrant microglial activation accounts for the
cerebral forms, whereas inﬂammation allegedly plays no role in AMN. How VLCFA accumulation leads to neu-
rodegeneration and what factors account for the dissimilar clinical outcomes and prognosis of X-ALD var-
iants remain elusive. To gain insights into these questions, we undertook a transcriptomic approach
followed by a functional-enrichment analysis in spinal cords of the animal model of AMN, the Abcd1
2 null
mice, and in normal-appearing white matter of cAMN and cALD patients. We report that the mouse model
shares with cAMN and cALD a common signature comprising dysregulation of oxidative phosphorylation,
adipocytokine and insulin signaling pathways, and protein synthesis. Functional validation by quantitative
polymerase chain reaction, western blots and assays in spinal cord organotypic cultures conﬁrmed the inter-
play of these pathways through IkB kinase, being VLCFA in excess a causal, upstream trigger promoting the
altered signature. We conclude that X-ALD is, in all its variants, a metabolic/inﬂammatory syndrome, which
may offer new targets in X-ALD therapeutics.
INTRODUCTION
X-linked adrenoleukodystrophy (X-ALD: McKusick no.
300100) is a neurometabolic genetic disorder characterized
by progressive demyelination within the central nervous
system (CNS), axonopathy in spinal cords and adrenal insufﬁ-
ciency. It is the most common monogenic leukodystrophy and
peroxisomal disorder with a minimum incidence of 1 in 17 000
males. The disease is caused by mutations in the ABCD1
(ALD) gene (Xq28) encoding for the peroxisomal ABC trans-
porter (1,2), which functions as a transporter of
very-long-chain fatty acids (VLCFAs) or VLCFA–CoA
esters into the peroxisome for degradation by b-oxidation (3).
Three major disease variants have been described: a
late-onset form affecting adults and called adrenomyeloneuro-
pathy (AMN) as it presents peripheral neuropathy and distal
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Advance Access published on November 17, 2011axonopathy in spinal cord with secondary demyelination—but
no brain demyelination—with spastic paraparesis as major
symptoms, and two ultimately lethal forms, with cerebral de-
myelination and neuroinﬂammation, an adult form called
cAMN, and an acute, childhood cerebral form called cALD.
Interestingly, all clinical phenotypes can occur within the
same family, that is, there is no phenotype–genotype correl-
ation (4). All X-ALD patients indeed accumulate saturated
VLCFAs and to a lesser extent, monounsaturated VCLFAs
in plasma and tissues, most notably in the brain and adrenal
cortex (5). VLCFAs are incorporated in complex lipids in
cell membranes and are thought to destabilize and break
myelin sheaths by occupying the lateral chains of proteolipid
proteins, gangliosides and phospholipids (5). Although
disease severity correlates with increased VLCFA contents
in white matter (6), it remains elusive how the excess of
VLCFAs causes the adrenal and spinal cord pathologies,
while acting or not as a trigger of central demyelination.
Thus, additional pathogenic factors critically shaping the clin-
ical manifestation of X-ALD ought to exist. The identiﬁcation
of these factors is one of the outstanding questions in X-ALD
and is essential to develop effective therapies.
Immunohistological analyses may provide clues as to
missing links between fatty acid accumulation and pathology.
Thus, a robust inﬂammatory response occurs in the brain white
matter in cALD, whereas minimal or no inﬂammatory lesions
have been reported in tissues from AMN patients (5). More-
over, a striking recovery has been recently described in
cALD patients upon infusion of genetically corrected hemato-
poietic stem cells (7). This ﬁnding lends strong credence to the
idea that microglia-driven inﬂammation causes cALD and
prompts the question: how does the metabolic dysfunction
lead to axonal damage and/or aberrant inﬂammation?
The mouse model of X-ALD is a classical knockout of the
Abcd1 gene, but it does not reproduce the phenotypic variabil-
ity observed in X-ALD patients, because it only exhibits a
late-onset neurodegenerative phenotype with axonopathy in
spinal cords and peripheral nerves, resembling a mild AMN
phenotype. The ﬁrst immunohistochemical evidence of
axonal degeneration and myelin pathology is detectable in
the mouse spinal cord after 20 months of age, but not in the
brain. This is concomitant to motor coordination impairment,
disability and slowing of peripheral nerve conduction veloci-
ties (8,9). As observed in ALD patients, Abcd1-deﬁcient
mice accumulate VLCFAs in the brain and the spinal cord
(10,11).
The Abcd1
2-deﬁcient mice thus provide a valuable model
to establish the molecular proﬁle of X-ALD at its earliest, pre-
symptomatic stages, wherein pathogenic factors presumably
build on. Likewise, we reason that tissues from non-affected
brain areas of X-ALD patients are key to accessing causative
events in disease pathogenesis. Thus, by using genome expres-
sion proﬁling and data mining of differentially expressed
genes, we have identiﬁed dysregulated pathways in the
spinal cord of Abcd1
2 mice and in non-affected white
matter tissue of X-ALD patients. The analysis unravels a
common metabolic abnormality signature both in the mouse
model and human patients, characterized by mitochondrial
dysregulation, insulin desensitization and an NF-kB-mediated
proinﬂammatory response. A literature perusal points to the
IkB kinase (IKK) as a hub linking these pathways. Thus,
IKK is activated by Toll-like receptors (TLRs) leading, on
the one hand, to insulin desensitization and, on the other
hand, to activation of NF-kB-dependent genes. Adipocyto-
kines, in turn, are strong inhibitors of TLR signaling. By the
combined use of quantitative polymerase chain reaction
(q-PCR) and western blots, we did conﬁrm in the mice the ac-
tivation of the TLR-IKK-NF-kB axis and the reduction in
insulin sensitization, concomitant to a decrease in the plasma
contents of the adipocytokines leptin and adiponectin. These
ﬁndings challenge the notion that inﬂammatory reactions
only occur in severe forms of X-ALD and provide a basis to
argue that a mostly benign inﬂammatory reaction initiated
by VLCFAs may adopt an aggressive proﬁle should a
second hit appear (12). Overall, our transcriptomic analysis
gives insights into the different molecular mechanisms operat-
ing in X-ALD phenotypes and provides clues as to mechan-
isms underlying the VLCFA-mediated inﬂammatory
responses. This may help to develop therapeutic strategies to
arrest the development of AMN into lethal forms.
RESULTS
We have analyzed: (i) spinal cords from Abcd1
2 mice at 3.5,
12 and 22 months of age to assess disease progression, (ii)
non-affected white matter from children with cALD and (iii)
non-affected white matter from adults with cAMN. In all
cases, samples from age-matched healthy individuals were
used as controls. First, mouse RNA probes were hybridized
to an array that consisted of 20 736 mouse cDNA clones repre-
senting  15 000 Unigene clusters, whereas human material
was hybridized to an Affymetrix Human Genome U133A
Array including 22 283 probe sets comprising 14 500
expressed sequence tags from human genes. We found differ-
ential gene expression between X-ALD samples and controls
upon using statistical linear models (see Materials and
Methods) to compare transcriptomic proﬁles of each genotype
and age. Next, we analyzed the functional enrichment of gene
ontology (GO) terms (http://www.geneontology.org) (13), and
the metabolic and cell signaling pathways extracted from the
Kyoto Encyclopedia of Genes and Genomes (KEGG) (http
://www.genome.jp/kegg/) (14). Finally, we identiﬁed the
X-ALD disease progression and signature common to mice
and patients based on the enrichment in biological functions
extracted from the previous analysis (Figure 1).
Deﬁnition of ALD disease progression and signature in mice
by GO and KEGG enrichment analyses
As shown in Supplementary Material, Figure S1, GO terms
signiﬁcantly enriched in Abcd1
2 mice at all ages were: (i) me-
tabolism with a prevalence of carbohydrate (tricarboxylic acid
cycle: GO:0006099; malate: GO:0006108, GO:0016615;
pyruvate metabolism: GO:0004743) and lipid metabolism
(fatty-acid synthase: GO:0004312; acyl-ACP thioesterase:
GO:0010281; lipid phosphatase activities: GO:0042577); (ii)
mitochondrial function with a focus on the respiratory chain:
GO:0006120, GO:0008121, GO:0008137, GO:0051539,
GO:0005743, GO:0005739, GO:0005746; and (iii)
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GO:0003735, GO:0005840, GO:0015935, GO:0005843; trans-
lational elongation: GO:0006414, GO:0003746, GO:0005853
and ribonucleoprotein complex: GO:0030529.
As shown in Supplementary Material, Figure S2, we
obtained the KEGG metabolic (S2A) or signaling (S2B)
pathway enrichment in ALD mice at the three ages, by
using either gene set enrichment analysis (GSEA) or
Figure 1. (A) A procedural diagram that indicates the pipeline followed to obtain the disease signature and progression in X-ALD mice and patients. (B)A
hierarchical clustering heat-map of the expression intensities of the signiﬁcantly regulated transcripts (on the Y-axis) versus the X-ALD patients and controls
arrays (on the X-axis). Interestingly, we observed a clear separation between X-ALD patients and controls suggesting that hX-ALD pathology is concomitant
to an alteration of transcriptional proﬁles.
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most remarkable ﬁnding is that many pathways were
changed at 3.5 months, more than 1 year prior to the ﬁrst
neuropathological signs. Most of the pathways changed their
expression over time following an up-down pattern whereby
there was upregulated expression at 3.5 months of age,
perhaps as a result of a compensatory mechanism that
cannot be sustained for a long time, with the subsequent down-
regulation at 12 months. Examples are: oxidative phosphoryl-
ation (OXPHOS system), 00190; glycolysis, 00010; citrate
cycle (TCA cycle), 00020; proteasome, 03050; and ribosome,
03010 pathways. Regarding late-disease events, at 22 months,
we found: (i) inﬂammatory response related to TGFb: 04350
and T-cell receptor: 04660 signaling pathways activation, (ii)
activation of the mammalian target of rapamycin complex-1
(mTORC1): 04150 and (iii) activated autophagic response:
04140, presumably as a result of an increase in cell debris
removal associated with tissue damage. Supplementary Mater-
ial, Figure S3 shows complete gene expression of selected
pathways with up-down proﬁles.
We deﬁne the X-ALD signature as the metabolic (S2A) or
signaling (S2B) pathways dysregulated at all ages under
study. Dysregulated metabolic pathways include: (i) carbohy-
drate metabolism impairment with particular dysregulation of
butanoate metabolism: 00650, TCA cycle: 00020, and glyoxy-
late and dicarboxylate metabolism: 00630; (ii) lipid metabolism
impairment with fatty acid metabolism: 00071, glycerophospho-
lipid metabolism: 00564 and sphingolipid metabolism: 00600
affected; (iii) amino acid metabolism dysregulation with
valine, leucine and isoleucine degradation: 00280; (iv) glycan
metabolism with glycan structures degradation: 01032 and
focused on N-glycan degradation: 00511; and (v) unbalanced
energy expenditure with altered OXPHOS: 00190 system.
Regarding the signaling pathways, the signature is charac-
terized by the dysregulation of adipocytokine: 04920,
insulin: 04910, mitogen-activated protein kinase: 04010 and
the TLR: 4620 signaling pathways. Other dysregulated path-
ways are involved in protein and transcript processing such
as aminoacyl-tRNA biosynthesis: 00970, proteasome: 03050,
protein export: 03060 and ribosome: 03010.
Deﬁnition of ALD signature in human samples
We set out to investigate transcriptome changes in brain white
matter that was disease-free by histopathological inspection
with Luxol fast blue (LFB) staining to detect normal-looking
areas as described (6,15). Evaluation of KEGG signiﬁcant
pathways in the differentially expressed transcriptome from
child and adult X-ALD patients revealed the following dysre-
gulated pathways (S4): (i) unbalanced energy expenditure with
OXPHOS: 00190, insulin: 04910 and adipocytokine: 04920
pathways altered; (ii) cell communication impairment with
focal adhesion: 04510 and adherens junction: 04520 dysregu-
lation; (iii) common dysregulated pathways involved in
protein and transcript processing such as aminoacyl-tRNA
biosynthesis: 00970 and ribosome: 03010; (iv) protein degrad-
ation by ubiquitin-mediated proteolysis: 04120; (v) immune
system response with complement and coagulation cascades
pathway: 04610 and antigen processing and presentation
pathway: 04612 activation; and (vi) induction of the
antioxidant response with affected expression of the glutathi-
one (GSH) metabolism pathway: 00480. The following path-
ways were thus dysregulated in both Abcd1
2 mouse and
human X-ALD: (i) adipocytokine signaling: 04920, (ii)
aminoacyl-tRNA biosynthesis: 00970, (iii) insulin signaling:
04910, (iv) OXPHOS system: 00190 and (v) ribosome:
03010 (Figure 2). Thus, there is a shared energy homeostasis
impairment and protein and transcript processing alteration
in mice and humans.
q-PCR validation of candidate genes belonging
to dysregulated pathways
To validate the pathways commonly dysregulated in Abcd1
2
mice and human X-ALD, we analyzed the transcript contents
of related genes with quantitative real-time PCR (qRT-PCR).
We measured gene expression of 3–4 candidate genes per
pathway in Abcd1
2 mouse spinal cords at the three ages
under study as follows:
(1) Adipocytokine signaling: Tnfrsf1a (tumor necrosis factor
receptor superfamily member 1A), Ikbkb (inhibitor of
nuclear factor kappa-B kinase subunit beta), NF-kB2
(nuclear factor NF-kappa-B p100 subunit) and Adipor1
(adiponectin receptor 1).
(2) Aminoacyl-tRNA biosynthesis pathway: Aars
(alanyl-tRNA synthetase), Gars (glycyl-tRNA synthetase)
and Sars (seryl-tRNA synthetase).
(3) Insulin signaling: Irs1, Irs2 (insulin receptor substrates 1
and 2) and Akt2 (RAC-beta serine/threonine-protein
kinase), which is a downstream effector of the insulin sig-
naling pathway.
(4) Oxidative phosphorylation: Ndufs7 [nicotinamide adenine
dinucleotide (NADH) dehydrogenase (ubiquinone) Fe-S
protein 7], Sdha (succinate dehydrogenase complex,
subunit A), Uqcrc1 (ubiquinol-cytochrome c reductase
Figure 2. Common dysregulated pathways in spinal cords of ALD mice at 3.5,
12 and 22 months, and cerebral white matter of child and adult ALD patients.
Signiﬁcant KEGG pathways were identiﬁed by using the statistics gene set en-
richment analysis (GSEA) (G) and hypergeometric distribution function (H).
Only the pathways statistically signiﬁcant in at least two tests are represented.
Black spots represent dysregulated pathway when probability value P is
,0.05 according to the H-test, which detects changes but does not inform
about their up or down direction. Red and green spots represent up- and down-
regulated pathway expression based on the G-test when probability value of P
is ,0.05, orange spots means dysregulated pathway based on the G-test with a
probability value of ,0.05, in case the gene set does not have a clear tendency
to be up- or downregulated. Blue circle means signiﬁcant pathway with a prob-
ability value of P , 0.0001.
Human Molecular Genetics, 2012, Vol. 21, No. 5 1065Figure 3. Validation of dysregulated pathways at three different ages in Abcd1
2 mice spinal cords. qRT-PCR measurements of (A) adipocytokine signaling
pathway, (B) aminoacyl-tRNA biosynthesis, (C) insulin signaling pathway, (D) oxidative phosphorylation and (E) ribosomal subunits. Ikbkb, NF-kB2,
Tnfrsf1a, Adipor1, Sars, Gars, Aars, Akt2, Irs1, Irs2, Ndufs7, Sdha, Uqcrc1, Cox4i1, Rps9, Rps27 and Rpl23 mRNA has been quantiﬁed by qRT-PCR. 18S
was used as an internal control. Signiﬁcant differences have been determined by Student’s t-test. Signiﬁcant differences are shown as ∗P , 0.05 and ∗∗P , 0.01.
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IV isoform 1).
(5) Ribosome: Rps9 (ribosomal protein S9), Rps27 (ribosomal
protein S27) and Rpl23 (ribosomal protein L23).
We found the differential expression of Ikbkb, NF-kB2,
Tnfrsf1a, Adipor1, Aars, Sars, Akt2, Irs1, Irs2, Ndufs7, Sdha,
Uqcrc1, Cox4i1, Rps9, Rps27 and Rpl23 (Figure 3).
The adipocytokines leptin and adiponectin were decreased
in Abcd1
2 mice
We next aimed at gaining further insights into
adipocyte-related dysregulation by measuring contents of
leptin and adiponectin, which are the most abundant adipocy-
tokines produced by adipocytes. We found that both leptin and
adiponectin were reduced in serum of Abcd1
2 mice at 12
months of age with respect to controls (Figure 4). Remarkably,
adiponectin is the only adipocyte-speciﬁc protein that is
known to be negatively regulated by obesity and to show
insulin-sensitizing properties with strong negative correlations
with multiple indices of insulin resistance (16). This, together
with the lower levels of adiponectin in Abcd1
2 mice, argues in
favor of a metabolic abnormality in X-ALD.
Insulin desensitization in Abcd1
2 mice spinal cords
To further investigate the insulin signaling pathway, we exam-
ined the protein contents and phospho-activation of enzymes
belonging to this pathway including IRS1, AKT, S6K and
JNK in Abcd1
2 mouse spinal cords at 12 months of age
(Figure 5A). Among other substrates, insulin stimulates the
phosphorylation in tyrosine of IRS proteins, the phosphoryl-
ation of which mediates insulin action and is often attenuated
in systemic insulin resistance, both in animal models and
human disease (for a review, see 17). We found no difference
between genotypes regarding IRS1 tyrosine phosphorylation
(data not shown) and the downstream effector AKT in
Thr308 and Ser473 phosphorylation, arguing against activa-
tion of the insulin pathway associated to the disease. Alterna-
tively, the phosphorylation of IRS1 in serine residues has been
proposed as a general mechanism of functional inhibition of
the IRS1 protein and, in particular, phosphorylation in
Ser307 has become a molecular indicator of insulin resistance
(18,19). To investigate whether Abcd1
2 mice manifest insulin
desensitization, we measured levels of IRS1 Ser307 phosphor-
ylation in Abcd1
2 mouse spinal cords at 12 months of age
(Figure 5A). Our results provide evidence that Ser307 phos-
phorylation was induced in Abcd1
2 compared with wild-type
(Wt) mice, suggesting reduced insulin sensitization in X-ALD
pathology.
Figure 4. Leptin concentration was lower in serum from Abcd1
2 mice (A).
Leptin (pg/ml) was measured in serum from 12-month-old Wt (n ¼ 8) and
Abcd1
2 (n ¼ 9) mice. Adiponectin concentration was also lower in serum
from Abcd1
2 mice (B). Adiponectin (mg/ml) was measured in serum from
12-month-old Wt (n ¼ 10) and Abcd1
2 mice (n ¼ 12). Statistical analysis
was done by Student’s t-test: ∗P , 0.05.
Figure 5. (A) Insulin signaling pathway in Wt and Abcd1
2 mouse spinal cords
at 12 months of age. Western blots to monitor contents of IRS1, p-IRS1
Ser307, AKT, p-AKT Thr308, Ser473, p-S6K Thr389, JNK and p-JNK
Thr183 and Tyr185 have been performed in whole spinal cord lysates from
Wt and Abcd1
2 mice (n ¼ 6 individuals per genotype). Representative blots
are shown. Statistical analysis was done by Student’s t-test: ∗P , 0.05. The
phosphorylation of IRS1 in Ser307 was induced in Abcd1
2 mice spinal cord
in the absence of insulin signaling activation, as shown by the lack of activa-
tion of kinases pS6K and JNK. (B) Phosphorylation of IRS1 ser307 in organo-
typic spinal cord slice culture (OSCSC). Western blots to monitor
phosphorylation levels of IRS1 ser 307 have been performed on whole
protein extracts from OSCSC (n ¼ 6 cultures per genotype, Abcd1
2 or Wt lit-
termates) incubated 24 h with BSA-conjugated C26:0 50 mM or BSA alone as
control. Representative western blots are shown. C26:0 induces the IRS1
Ser307 phosphorylation in Wt but not Abcd1
2-derived OSCSC.
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Fatty acids (FAs) can mediate insulin desensitization asso-
ciated with the phosphorylation of IRS1 on serine 307
(17,20,21). Because X-ALD pathology shows an accumulation
of VLCFAs, it seemed likely that the FAs caused insulin
desensitization. Hexacosanoic acid (C26:0) is the major
VLCFA accumulated in X-ALD and can perturb the physio-
logical properties of membranes, and it has been demonstrated
to exert toxic effects in rat primary neuronal cell cultures and
human ﬁbroblasts (22,23). We evaluated the effect of C26:0
(10–100 mM, a 24-h incubation) on IRS1 phosphorylation in
serine 307 using organotypic slice cultures of spinal cord
(OSCSC). In OSCSC from Wt mice, 50 mM C26:0 induced
an increase in IRS1 Ser307 phosphorylation, thus conﬁrming
our hypothesis that VLCFAs may trigger insulin desensitiza-
tion (Figure 5B). In contrast, the Abcd1
2 OSCSC did not
respond to C26:0 treatments, even at the higher dose of
100 mM. This suggests that IRS1 phosphorylation in these
slices cannot increase over the sustained phosphorylation
found in basal conditions, which largely exceed that of
control slices.
IKK-mediated insulin desensitization in Abcd1
2 mice
It has been reported that S6K, JNK and IKKb inhibit insulin
actions by phosphorylating IRS1 on serine (18,19,21). Control
overinsulinsignalingisachievedbyanautoregulatoryfeedback
loop whereby S6K, a downstream effector of mTOR, inhibits
upstream elements, a process known as homologous desensi-
tization. Findings in S6k
2 mouse model suggest that
nutrient-induced S6K activation acts to suppress insulin signal-
ingthroughmodulatingIRS1Ser307andSer636/639phosphor-
ylation (21). Alternatively, mounting evidence indicates that
activationofJNKiscentral tothedevelopment ofinsulinresist-
ance in response to obesity mediated by fatty acid excess, by
phosphorylating IRS1 in serine (for a review, see 17). To
address whether S6K or JNK can induce insulin desensitization
inAbcd1
2miceat12monthsofage,weexaminedtheactivation
status of S6K and JNK in Wt and Abcd1 knockout mice by
western blot with speciﬁc anti-phospho-antibodies (that recog-
nize P-Thr389 in the case of S6K and P-Thr183 and P-Tyr185
for JNK). We did not ﬁnd any change in the activation of S6K
or JNK in Abcd1 knockout mice (Figure 5A), suggesting that
these kinases do not contribute to the phosphorylation of IRS1
Ser307 and, subsequently, to the insulin desensitization. Alter-
natively, we also examined IKK activation in our model. Our
results show that total levels of IKKa, IKKb and IKKg (the
three components of the IKK complex) are consistently
increased in Abcd1 knockout mice compared with control
mice.WealsofounddetectablelevelsofactiveIKKspeciﬁcally
inthe mutant animals, as measured with an antibody that recog-
nizes both phosphorylated IKKa and IKKb (Figure 6). To
further conﬁrm that this phosphorylated IKK found in the
Abcd1
2 mice was active, we examined by western blotting the
levels of total and phosphorylated IkBa protein, which is the
main target of this kinase complex. Our results demonstrate
that mutant mice show a slight but signiﬁcant reduction in the
total IkBa protein levels accompanied by increase IkBa phos-
phorylation, indicative of the activation of canonical IKK
complex. These results also indicate that IKK is a good
candidate to mediate phosphorylation of IRS1 in Abcd1
knockout mice.
TLR/NF-kB2 pathway was induced in Abcd1
2 mice
TLRs are a family of pattern-recognition receptors that play a
critical role in the innate immune system by activating proin-
ﬂammatory signaling pathways such as the NF-kB through
IKK activation in response, for instance, to microbial patho-
gens. In our microarray analysis, we found that different ele-
ments of the TLR pathway were dysregulated in our mouse
model at all ages under study. Similarly, adult X-ALD patients
showed increased expression of the TLR2 (1.3-fold, P ,
0.001) and the TLR4 coreceptor CD14 (4.5-fold, P , 0.001).
These ﬁndings are in agreement with activation of the IKK
complex in Abcd1 knockout mice. Moreover, microarray ana-
lysis demonstrated that Nfkb2, a well-characterized target of
the NF-kB pathway, was upregulated in Abcd1
2 mice at 3.5
and 12 months and downregulated at 22 months of age,
which was further conﬁrmed by qRT-PCR (Figure 3). By
western blot analysis, we demonstrated that p100 (the
product of the Nfkb2 gene) protein levels were signiﬁcantly
increased in mutant mice compared with the controls. Most
importantly, not only p100 levels, but also the amounts of
its active form p52 (involved in the non-canonical NF-kB sig-
naling), were signiﬁcantly upregulated in Abcd1
2 spinal cords
at 12 months of age (Figure 6). Together, these results indicate
Figure 6. Activation of kinases IKK in mouse spinal cord (SC) at 12 months
of age. Western blots to monitor levels of IKKa, IKKb, IKKg, NF-kB2 (p100/
p52) and IkBa were performed in whole spinal cord lysates from Wt and
Abcd1
2 mice (n ¼ 6 individuals per genotype). Activated IKKs phosphorylate
IkBa that liberates the NF-kB complex, which subsequently translocates into
the nucleus.
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active in Abcd1 knockout mice and suggest a TLR-mediated
induction of the IKK complex leading to gene transcription
of proinﬂammatory cytokines. To substantiate our microarray
ﬁndings, we used a qRT-PCR array (SABioscience) to
measure expression of TLRs, NF-kB genes, several cytokines
and their receptors at 12 months of age in the Abcd1 null mice.
TLRs such as Tlr5 and Tlr8, together with some of their adap-
tors, interactors or effectors (Elk1, Irf3, Nr2c2 and Peli1) were
induced in Abcd1 null mice (Figure 7). Activation of NF-kB
was conﬁrmed by inductions of its messenger and further by
induction of its target proinﬂammatory cytokines RANTES
(Ccl5), Tnf and Il1b (Figure 7).
Oxidative stress underlying disease progression
Previous studies from our laboratory demonstrate that oxida-
tive stress contributes to the progression of X-ALD
(11,22,24,25). To compare our transcriptomic data with the
knowledge derived from functional studies in the ﬁeld, as a
means of reverse validation, and in the absence in KEGG of
pathways encompassing all enzymatic and signaling stress-
related pathways, we directly assessed whether differentially
expressed data, as detected by GSEA analysis in Abcd1
2
mice, were enriched in genes involved in oxidative stress.
First, we created a gene list by retrieving genes related to oxi-
dative stress from the literature, text mining and manually
curated data (407 genes; see Supplementary Material,
Figure S5). We then compared this list against our differential
data and found that the selected genes were more frequently
differentially expressed in mice at all ages than it would be
expected by random with a P-value of ,0.001. This conﬁrms
that oxidative stress in the spinal cord is a signature common
to all ages that may contribute to ALD disease progression. Of
note, mitochondria are a primary source generating the react-
ive oxygen species (ROS) superoxide (O2
2) and thus may play
a central role in Abcd1
2 ROS production. We observe that as a
whole, the mitochondrial transcriptome is largely dysregulated
(Figure 8). Several enzymes so far known to generate ROS are
dysregulated (26). In particular, we identiﬁed the induction of
the tricarboxylic acid (TCA), a-ketoglutarate dehydrogenase
(dihydrolipoamide S-succinyltransferase—DLST) (27) or the
respiratory chain, and the repression of the TCA enzymes oxo-
glutarate dehydrogenase (OGDH)) and the aconitase 2 (ACO)
at 3.5 months of age, as depicted in Figure 8. Moreover, the
antioxidant defence system to detoxify the ROS seems to be
differentially dysregulated. Enzymatic components induced
in Abcd1
2 spinal cords include glutathione peroxidases
(GPX), phospholipid hydroperoxide glutathione peroxidase
(PGPX), several glutathione S-transferases (GSTs), peroxire-
doxins (PRX), glutaredoxins (GRX) and thioredoxins (TRX).
In addition, the glutathione synthesis seems to be impaired
because the expression of the key enzymes glutamate-cysteine
ligase catalytic subunit (GCLC) and glutathione synthetase
(GSS) are repressed (see Supplementary Material, Figure S6
for expression values at 3.5 months of age). The observed in-
duction of the enzymatic glutathione antioxidant system that
consumes the reduced GSH, together with the repression of
GSH biosynthesis, lends support to a GSH depletion scenario,
which commonly occurs during oxidative stress situations.
This has been experimentally veriﬁed in (24). Of note, the pre-
dicted mitochondrial dysfunction and dysregulation of calcium
signaling as depicted in Figure 8 is in agreement with the
effects observed in primary neural cells challenged with
excess of VLCFAs (23).
An integrative depiction of the validated pathways and their
cross-talk is shown in Figure 9. These data should serve as a
platform for an improved understanding of physiopathogenesis
and thus for rational therapeutic design against this dreadful
disease.
DISCUSSION
We have identiﬁed the main metabolic and cell signaling path-
ways playing a potential role in X-ALD pathogenesis based on
a functional-enrichment analysis of transcriptomic data from
Abcd1
2 mice and human X-ALD patients. Mice and humans
share a signature that encompasses mitochondrial dysregula-
tion, ROS production with antioxidant defense impairment,
insulin and adipocytokine signaling dysregulation, protein
synthesis and turnover dysregulation and an NF-kB mediated
proinﬂammatory response ampliﬁed by the activation of the
TLRs. A most relevant ﬁnding is that pathway dysregulation
was detected in the mice as early as 3.5 months, more than
a year before the ﬁrst neurological symptoms appears, and
in human brain samples from regions not affected by the
disease yet. We thus conclude that the dysregulated pathways
may contribute to the X-ALD disease and VLCFA excess
might act as a ﬁrst causative factor of the cellular mechanism
underlying X-ALD pathology. The mechanisms by which
Figure 7. Activation of TLR/NF-kB in mouse spinal cords at 12 months of age. A q-PCR was performed to measure a gene array including TLRs, TLR adaptors,
NF-kB forms, several cytokines and their receptors. Only differentially expressed genes are shown (n ¼ 6 individuals per genotype). The data point to a general
activation of TLR/NF-kB pathways, wherein we highlight the upregulation of Tlr8, Tlr5, Nfkbib, RANTES (Ccl5), Ccr1, Ccr2, Ccr7, Il1b, Tnf and Lta. Signiﬁ-
cant differences have been determined by Student’s t-test: ∗P , 0.05, ∗∗P , 0.01 and ∗∗∗P , 0.001.
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dysfunction, insulin resistance and immune responses are trad-
itionally studied in classical metabolic organs such as liver,
adipose or muscle tissues, whereas their role in CNS has
seldom been addressed. X-ALD constitutes a bona ﬁde
model in which to study the impact of VLCFA accumulation
in the CNS, as well as in the adrenal cortex. Our results
may help to decipher the cellular mechanisms contributing
to X-ALD pathology with positive implications for therapy.
A working model hypothesis is depicted in Figure 9. Below
the main tenets are discussed.
VLCFAs cause oxidative stress and mitochondrial
dysregulation
We have proposed that VLCFA-mediated oxidative stress is a
causative agent in X-ALD physiopathogenesis. We have pre-
viously shown signs of oxidative damage in spinal cords
from the Abcd1-null mice and in ﬁbroblasts from X-ALD
patients, with oxidative, glycoxidative and lipoxidative
damage to proteins and altered expression levels of enzymatic
antioxidant defences such as glutathione peroxidase 1 (GPX1)
and superoxide dismutases 1 and 2 (22). Second, we have
Figure 8. The role of oxidative stress in ALD progression in spinal cord is already manifesting as early as 3.5 months of age. The picture shows dysregulated
gene expression, induced (red triangle) and repressed (green triangle), of processes and components involved in ROS generation (black stars) and antioxidant
defense (white stars). Perturbations in oxidative phosphorylation, iron and calcium homeostasis and changes in GSH homeostasis may altogether represent causes
and consequences of increased oxidative stress. ROS might activate NF-kB leading to the regulation of genes involved in cell survival and inﬂammation.
12-Hydroxyeicosatetrenoate (12-HETE), arachidonate 12-lipoxygenase (ALOX12), ATPase, Ca
2+ transporting, cardiac muscle, slow twitch 2 (ATP2A2),
ATPase, Ca
2+ transporting, plasma membrane 1 (ATP2B1), calcium-channel, voltage-dependent, alpha 2/delta subunit 3 (CACNA2D3), calcium-channel,
voltage-dependent, gamma subunit 5 (CACNG5), calcium-channel, voltage-dependent, L-type, alpha 1D subunit (CACNA1D), calcium/calmodulin-dependent
protein kinase (CaM kinase) II delta (CAMK2D), calmodulin 1 (CALM1), protein phosphatase 3, catalytic subunit, alpha isoform (PPP3CA), ceruloplasmin
(CP), coenzyme Q10 (CQ), coproporphyrinogen oxidase (CPOX), cystathionine beta-synthase (CBS), cytochrome b-245 (CYBA), cytochrome c (CytC),
DLST, dihydroxyacetone-phosphate (DHAP), electron transport chain complexes I:V (C-I:C-V), epoxide hydrolase 1, microsomal (EPHX1), glucose-6-
phosphate dehydrogenase X-linked (G6PDH), GCLC, GRX, GSH, glutathione disulfide (GSSG), GPX, glutathione reductase (GSR), GST, GSS,
glyceraldehyde-3-phosphate (G3P), glycerol-3-phosphate dehydrogenase (GPDH), glyoxalase 1 (GLO1), glyoxylate reductase/hydroxypyruvate reductase
(GRHPR), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (NFKBIA or IkBa), conserved helix–loop–helix ubiquitous
kinase (CHUK or IKKa), inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (IKBKB or IKKb), inhibitor of kappa light polypeptide
gene enhancer in B-cells, kinase gamma (IKBKG or IKKg), lipid hydroperoxide (LOOH), lipid hydroxide (LOH), malic enzyme (ME), NADPH oxidase 1
(NOX1), nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 and 2 (NF-kB1 and NF-kB2), OGDH, PRX, phosphodiesterase 1A, calmodulin-
dependent (PDE1A), PGPX, phosphorylase kinase, alpha 1 (PHKA1), pyruvate dehydrogenase (PDH), solute carrier family 8 (sodium/calcium exchanger),
member 1 (SLC8A1), thioredoxin (TRX), TCA, triosephosphate isomerase 1 (TPI), uncoupling protein 2 (UCP2), uroporphyrinogen decarboxylase (UROD),
uroporphyrinogen III synthase (UROS).
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ﬁve key enzymes of glycolysis and TCA cycle in Abcd1
2
mice and human X-ALD ﬁbroblasts. Third, NADH and adeno-
sine triphosphate (ATP) levels are signiﬁcantly diminished in
these samples, together with decrease in pyruvate kinase activ-
ities and GSH levels, and increase in NADPH (24). Fourth,
anti-oxidant treatment largely erases signs of oxidative
damage and halts axonal degeneration and disability of
Abcd1 null mice (25). Finally, a wide array of mitochondrial
genes related to the pyruvate and OGDH complexes, TCA
cycle, OXPHOS system and different organelle antioxidant
defenses are dysregulated according to previous (22,24) and
present transcriptome data (see Figure 8). There is also immu-
nohistochemical evidence of oxidative stress and damage in
brains from cALD and cAMN patients, mainly resulting
from lipid peroxidation, and mostly occurring in the
inﬂammatory demyelinated lesions, as well as in adrenal
cortex (28,29). The accumulation of excess lipid, in particular,
saturated FA, may damage cells by causing stress on mem-
branes of lipid-metabolizing organelles, especially mitochon-
dria. In particular, VLCFAs are found as lateral chains of
complex lipids, such as phosphatidylcholine and phosphatidy-
lethanolamine, thus playing a main structural role as compo-
nents of cellular membranes (30–32). We propose that
VLCFAs in the mitochondrial membranes might induce a
stress response leading to the production of ROS and oxidation
of main protein components of Krebs cycle contributing all to-
gether to a mitochondrial dysregulation, sinking of ATP levels
and the collapse of energy homeostasis (24). Our transcrip-
tomic analysis aligns with previous experimental data
showing the impaired energy production and dysregulated or-
ganelle antioxidant defenses (11,22,24,25).
Figure 9. Proposed model for X-ALD disease mechanism. Taking together our functional validation that ensued our transcriptomic data mining and the experi-
mental evidence provided, we put forth the following model: disease progression appears mediated by the successive action of a primarily VLCFA excess, mito-
chondrial dysregulation combined with ROS production and antioxidant defenses depletion, insulin desensitization, TLR activation and NF-kB-mediated
proinﬂammatory response. The increased lipid load induces a stress response leading to the production of ROS contributing all together to a mitochondrial dys-
regulation. The activation of IKKs links VLCFA-induced metabolic deﬁciency with an NF-kB-mediated proinﬂammatory response. IKK activation desensitizes
insulin signaling via phosphorylation of IRS1 on serines. Insulin controls glucose uptake through tyrosine phosphorylation of insulin receptor substrate (IRS)
proteins. Activation of phosphatidylinositol 3-kinase (PI3K) and generation of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) activates AKT. But
IRS1 serine phosphorylation attenuates insulin sensitivity and subsequently decreases glucose uptake and insulin-induced metabolism. IKKs can be induced
by FA via the activation of TLRs and PKC, and the latter can be activated by DAG. The low levels of adiponectin might contribute to the increased proinﬂam-
matory response in X-ALD by reducing the inhibitory adiponectin effect on TLR signaling.
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Our ﬁndings point to IKK-mediated insulin desensitization in
X-ALD. IRS1 serine phosphorylation attenuates insulin sensi-
tivity and subsequently decreases glucose uptake and
insulin-induced metabolism. Indeed, IRS1 serine phosphoryl-
ation seems to be associated with increased free fatty acids
levels since IRS1 Ser307 phosphorylation has been induced
in muscle, white adipose tissue and liver tissues of mice fed
a high-fat diet (20,21). Although the phosphorylation of
IRS1 Ser307 has been associated to insulin resistance
(18,19), the phosphorylation of IRS1 Ser307 observed in
spinal cords of Abcd1
2 mice points to insulin desensitization
but not resistance, because an intraperitoneal glucose tolerance
test has repeatedly shown no differences between genotypes
(Supplementary Material, Figure S7). IRS1 Ser307 is reported
to be a phosphoacceptor of S6K, JNK and IKK (18,19,21).
Our ﬁndings point out IKK-mediated IRS1 phosphorylation
in Ser307 in X-ALD. A direct link between FA and IKK acti-
vation has formerly been proposed with the accumulation of
intracellular fatty acyl-CoA and diacylglycerol (DAG),
which can activate protein kinase C (PKC) u in muscles or
PKCd in the liver (33,34), which in turn activate IKK contrib-
uting to insulin resistance (17). In addition, the chronic pro-
duction of ROS species due to excess of VLCFAs (22) can
lead to abnormal changes in intracellular signaling and result
also in insulin resistance via phosphorylation of IRS proteins
by stress-sensitive kinases such as IKKb (35).
TLR/NF-kB2 pathway stimulates a proinﬂammatory
phenotype via IKK
We demonstrated that the product of the NF-kB gene, p100
and its active form p52, was signiﬁcantly upregulated in
Abcd1
2 mice spinal cords. These results, together with the
IKK complex induction, indicate that NF-kB pathway is
active in Abcd1 knockout mice leading to gene transcription
of proinﬂammatory cytokines such as RANTES (CCL5),
TNF and IL-1b. Of note, our data are in agreement with a pre-
vious report, which established a link between VLCFA accu-
mulation and inﬂammation in astrocytes. Inactivation of
Abcd1 and Abcd2 genes induced an inﬂammatory response
mediated by transcription factors NF-kB, AP-1 and C/EBP
(36). TLRs are a family of pattern-recognition receptors that
play a critical role in the innate immune system by activating
proinﬂammatory signaling pathways such as the NF-kB
through IKK activation in response to microbial pathogens.
Our microarray analysis indicates that different elements of
the TLR pathway were dysregulated in our mouse model
and, in particular, showed altered expression of TLR2 and
the TLR4 coreceptor CD14 in cAMN patients as in other neu-
rodegenerative diseases (37,38). Indeed, there is an evolution-
arily conserved overlapping of pathways that regulate
metabolic and immune functions through common key regula-
tory molecules and signaling systems (39). This may allow
nutrients such as FA to act through pathogen-sensing
systems such as TLRs, giving rise to metabolically or nutri-
tionally induced inﬂammatory responses (20,40). It is worth
mentioning that, like macrophages, microglial cells express
TLRs, respond to TLR ligands and produce proinﬂammatory
mediators. This is highly relevant to X-ALD pathology
because microglial cells are thought to be the main type of
the innate immune system in the nervous tissue and able,
when replaced by hematopoietic stem-cell transplantation or
gene therapy, to arrest inﬂammatory demyelination (41). It
is tempting to speculate that the VLCFAs accumulated due
to Abcd1 inactivation could activate TLR signaling leading
to NF-kB-induced proinﬂammatory response in X-ALD with
the subsequent activation of RANTES (CCL5), TNF and
IL-1b as shown. In fact, both histologically normal-appearing
areas as well as inﬂammatory areas of childhood ALD brains
show increased levels of proinﬂammatory cytokines TNF,
IL-1b, IL-6 and IL-2, indicating a primary relationship
between the metabolic abnormality and inﬂammation in the
disease progression (42).
Downregulation of adiponectin contributes to the
proinﬂammatory state
We have detected lower levels of adiponectin and leptin in
X-ALD mice. Adipocyte-derived adipocytokines are key
molecules linking metabolism and inﬂammatory response. It
is tempting to speculate that the VLCFAs and/or other lipid
metabolites accumulated due to the Abcd1-transporter inacti-
vation might reduce the levels of adiponectin contributing to
the increased proinﬂammatory response in X-ALD. Unlike
leptin and TNF, adiponectin has an anti-inﬂammatory effect
as shown by the capacity to suppress the synthesis of TNF
in endothelial cells and to induce the production of anti-
inﬂammatory cytokines such as IL-10 and IL-1 receptor antag-
onist (IL-1RA) in human monocytes, macrophages and den-
dritic cells (16,43). In addition, adiponectin suppresses
TLR-induced NF-kB activation in macrophages (44). There-
fore, the lower levels of adiponectin in Abcd1 null mice
might account for a compromised anti-inﬂammatory reaction
to counteract NF-kB-mediated inﬂammatory response
induced by TLR signaling.
In contrast to leptin, adiponectin does not cross the blood–
brain barrier in mice and is not detectable in human cerebro-
spinal ﬂuid. However, we detected overexpression of the adi-
ponectin receptor Adipor1 in spinal cords of Abcd1
2 mice by
qRT-PCR. In agreement with these ﬁndings, it has been
demonstrated expression of adiponectin receptors in brain
endothelium and the reduction of IL-6 secretion in brain endo-
thelial cells upon treatment with adiponectin (45).
Is inﬂammation in X-ALD good or bad?
Having demonstrated that a proinﬂammatory reaction lurks in
X-ALD prior to the development of axonopathy, in the case of
the mouse model with an AMN-like phenotype, or aberrant
microglia activation and demyelination, in the case of
cAMN and cALD patients, the question arises whether this
early inﬂammation contributes or not to the ensuing tissue
damage. In general, the role of the immune system in neurode-
generation is still highly debated. It has been demonstrated
that acute TLR activation via lipopolysaccharide administra-
tion regulates processes required to efﬁciently eliminate cell
debris and promote repair in the brain. These events increase
the recruitment of oligodendrocyte progenitor cells, favor
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rapid clearance of myelin debris or toxic elements from the
brain, microglial cells can react differentially and mount a
proinﬂammatory response that is detrimental for neurons and
astroglia, resulting in demyelination, synaptic dysfunction
and ultimately neurodegeneration (46). There is an increasing
body of evidence in support that TLR signaling mediates acti-
vation of microglia and the release of proinﬂammatory mole-
cules leading to neurotoxic processes in the course of various
CNS diseases. For instance, neurotoxic effects of TLR activa-
tion have been observed in speciﬁc regions of the brain during
chronic conditions such as in Alzheimer’s disease where Ab
ﬁbrils bind to CD14 and activate microglia (47) and
anti-CD14 strategies reduce the Ab-stimulated microglia
neurotoxicity (48). Thus, the TLR-induced activation of
microglia in nervous tissue depends on a subtle balance
between beneﬁcial and harmful effects and the long-term con-
sequences of such TLR activation, in particular, in X-ALD,
have yet to be investigated. Future studies in mice using
pharmacological inhibitors to suppress NF-kB activation
(e.g. salicylates that inhibit IKKb (49) or treatment with adi-
ponectin to block TLR pathways) will shed light on whether
the early proinﬂammatory phase of X-ALD is neuroprotective
or, in the contrary, contributes to axonopathy. In the latter
case, an anti-inﬂammatory regime should complement the
antioxidant therapies that have proven successful in the
Abcd1
2 mice (25).
Whatever the role of inﬂammation in the adult axonopathy,
an inevitable question is whether a connection between the pre-
symptomatic inﬂammation and the robust, deadly inﬂammation
in cAMN and cALD exists. A key idea is that activation of
microglia to highly deleterious states depends on the sequential
appearance of at least two hits, the ﬁrst one rendering microglia
mildly activated, thus priming its response to ensuing hits. A
precedent for this scenario exists in Alzheimer’s disease
animal models, wherein it has been shown that systemic
inﬂammation-mediated increase of Fc receptors in microglia
increases its reaction to Ab (50). We thus posit that
VLCFA-stimulated microglia in X-ALD may present a more
robust response to a second stimulus of yet unknown nature,
thus producing the switch from AMN to cAMN and cALD.
In the absence of the second hit, the inﬂammatory reaction
may proceed with its natural course and enter the repair- and
phagocytosis-prone phase, where microglia is deactivated and
produces anti-inﬂammatory cytokines. A resolution of the in-
ﬂammatory process would explain why lack of inﬂammatory
lesions has been reported in post-mortem tissues from AMN ter-
minal patients leading to the widespread misconception hitherto
that AMN, unlike cALD, is a non-inﬂammatory condition (4).
Overall, the discovery of a dysregulated pathway signature
common to Abcd1
2 mice, cAMN and cALD points to the exist-
ence of a basal pathogenic mechanism in X-ALD leading to
either AMN (or the AMN-like condition in the mouse) or to
the cerebral forms in humans.
In conclusion, our analyses pave the way for the character-
ization of VLCFA-mediated inﬂammation in the CNS and the
identiﬁcation of immunomodulatory therapeutic targets to halt
AMN progression and conversion into more severe forms. The
results highlight, in any event, the existence of a metabolism-
mediated inﬂammatory response that may provide insights
into the X-ALD pathogenesis, but also into the progression
of other neurodegenerative diseases featuring a link between
FA excess and neuroinﬂammation.
MATERIALS AND METHODS
Mouse breeding
The generation and genotyping of Abcd1
2/2 mice have been
previously described (8,9,11,51). Mice used for microarray
experiments were on a pure C57BL/6J background. Animals
were sacriﬁced, and spinal cords were recovered and con-
served at 2808C. Total RNA for microarrays analysis was
extracted using RNeasy Kit (Qiagen, Valencia, CA, USA)
from four animals at 3.5, three at 12, four at 22 months of
age and 11 Wt, age-matched Abcd1
2 spinal cords. All
samples were hybridized in duplicate and analyzed in dye
swap. All methods employed in this study are in accordance
with the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH Publi-
cations No. 85-23, revised 1996).
Custom cDNA microarray for X-ALD mouse
A cDNA microarray was manufactured at IGBMC (Institut de
Ge ´ne ´tique et de Biologie Mole ´culaire et Cellulaire). The array
consisted of 20 736 mouse cDNA clones representing
 15 000 Unigene clusters. The clones were selected from
public cDNA libraries, the NIA 15K (http://lgsun.grc.nia.nih.
gov/cDNA/cDNA.html) and the IMAGE collection
(http://image.llnl.gov/). Some clones were also acquired
from a private cDNA library collection (C. Benoist, Joslin
Diabetes Center, Boston, MA, USA). The cDNAs were amp-
liﬁed by PCR using vector-speciﬁc primers, puriﬁed using
MultiScreen FB ﬁlter plates (Millipore, Billerica, MA, USA)
and veriﬁed by gel electrophoresis. After dehydration, PCR
products were resuspended in the spotting buffer (75% forma-
mide and 25% water) and spotted in duplicate onto Ultra-
GAPSTM amino-silane-coated slides (Corning BV,
Schiphol-Rik, the Netherlands) using a MicroGrid II Arrayer
(BioRobotics Ltd, Cambridge, UK). The printed slides were
dried for 48 h and cross-linked by UV at 600 mJ/cm
2.
For probe synthesis in the dye swap experiments, total RNA
(200 ng) was ampliﬁed by linear PCR and the ampliﬁcation
products were labeled with dUTP-Cy3 and dUTP-Cy5 by
random priming (Bioprime, Invitrogen). Labeled cDNAs
were puriﬁed using Nucleospin Extract II columns (Macherey
Nagel, Du ¨ren, Germany) and hybridized in a Discovery station
using ChipHybe 80 hybridization buffer at 428C for 12 h
without any ﬁnal stringency washes (hybridization automate,
reagents and microarray hybridization procedure are from
Ventana Medical System, Tucson, AZ, USA).
Arrays were scanned using ScanArray 4000 (Packard Bio-
chips, Billerica, MA, USA) and images quantiﬁed using
Imagene 5.0 (BioDiscovery Microarray Bioinformatics Soft-
ware, Marina Del Rey, CA, USA). Detailed information is
available on the IGBMC microarray web site (http://www-m
icroarrays.u-strasbg.fr) (52).
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Brain tissues from ALD patients and age-matched controls
were obtained from the Brain and Tissue Bank for Develop-
mental Disorders at the University of Maryland, Baltimore,
MD, USA. Frozen blocks of normal-appearing white matter
were dissected from frontal or parietal lobes from 20 controls
and 21 ALD patients. All the children and adults with cerebral
ALD had the conventional ‘parieto-occipital’ form of cerebral
ALD. White matter sections of ALD patients and controls
were stained with LFB to detect demyelination, demyelination
edge and normal-looking area. Brain tissue sections were pro-
cessed when two to three adjacent sections showed no sign of
demyelination with LFB staining and no perivascular cuffs of
lymphocytes using hematoxylin and eosin staining (6,15).
RNA isolation and microarray processing of human ALD
samples
Total RNA was extracted from 41 frozen white matter samples
(including some replicate samples from some donors) obtained
from cALD (7 samples), child controls (8 samples), adult
cAMN (14 samples) and adult controls (12 samples) using a
Polytron type homogenizer (YellowLine DI 25 Basic) and
TriZol reagent (Invitrogen, Paisley, UK) in a ratio of 1 ml of
TriZol to 20 mg of tissue. RNA was further puriﬁed using
RNeasy mini-columns (Qiagen, Valencia, CA, USA) includ-
ing on-column DNAse-1 step and elution in water. The quan-
tity of extracted RNA was determined by spectrophotometry,
and quality was assessed using an Agilent 2100 Bioanalyzer
(South Plainﬁeld, NJ, USA). Insufﬁcient RNA yield was
achieved for seven samples, which were not progressed to
the microarray analysis. For the remaining 34 samples, 7 mg
of total RNA was processed to Biotin-labeled cRNA and
hybridized to HG-U133A GeneChips in accordance with the
Affymetrix protocol (Affymetrix, Santa Clara, CA, USA).
Arrays were scanned on a GeneChip Scanner 3000, and ﬂuor-
escence intensity for each feature of the array was obtained by
using GeneChip Operating Software (Affymetrix). Following
standard MAS5.0 Affymetrix quality control criteria, ﬁve
samples failed quality control (b-actin 3′/5′ ratios . 4), four
samples were identiﬁed as outliers using principal component
analysis (representing probable grey matter contamination)
and one ﬁle was lost during transfer. As a result, 24 samples
were progressed into statistical analysis (3 cALD, 3 child con-
trols, 8 cAMN and 10 adult controls) (Table 1).
Microarray data normalization and differential expression
analysis
Pre-processing of raw data and statistical analyses were per-
formed using Bioconductor packages in R programming envir-
onment (53) and custom software written in Perl. For mouse
arrays, background correction was performed using the
‘normexp’ method implemented in the Bioconductor
LIMMA package to adjust local median background estimates
(54). Background-corrected intensity data were normalized
using the Print-tip loess method to remove the bias within
each array and the A-values quantile normalization (Aqua-
ntile) to remove the bias between arrays.
To determine the target genes that are differentially express
at 3.5, 12 and 22 months in ALD mouse spinal cords, Abcd1
2
and Wt proﬁles for each age were compared using statistical
linear model in LIMMA. It was estimated the intra-spot correl-
ation between the two channels by using the function ‘intras-
potCorrelation’ and further the regression function ‘lmscFit’
ﬁtted a linear model to the two-color data. To calculate differ-
ential expression, P-values were computed by empirical Bayes
moderated t-statistics at a level of 0.05.
For human Affymetrix arrays, we read CEL ﬁles and then
corrected background, summarized and normalized the data
by robust microarray analysis method. Further, we estimated
the fold change and standard errors by ﬁtting a linear model
(using the lmFit function) for each gene given the groups of
arrays and then compute a moderated t-statistics of differential
expression by applying empirical Bayes at a level of 0.05. We
corrected t-test P-values for multiple hypotheses testing by
calculating the false discovery rate (P , 0.05).
The microarray experiments have been deposited in the
Array Express Database under accession numbers
E-MTAB-79 and E-MEXP-3288.
Functional enrichment analysis
Enrichment analysis detects whether a certain GO term or
KEGG pathway occurs more frequently in the set of genes
than it would be expected based on the frequency of its occur-
rence in the entire Chip. The Chip spotted transcripts were
annotated by Annbuilder package for getting GO terms, and
by KEGG package and custom software written in Perl and
R for pathway annotation. To evaluate which pathways or
functional categories were enriched in ALD mice, we com-
puted the Gene set enrichment analysis (‘geneSetTest’ func-
tion) and hypergeometric distribution test (GOHyperG and
‘phyper’ functions). We used P , 0.05 as the cutoff point to
determine whether GO term or a KEGG pathway was signiﬁ-
cantly enriched.
GeneSetTest function from Limma package tests whether a
set of genes is enriched for differential expression. Its prin-
ciple is the same as for Gene Set Enrichment Analysis intro-
duced by Mootha et al.( 55), but the statistical tests used are
different. It is based on a set of probe-wise t-statistics
arising for microarray analysis. We have computed four differ-
ent tests: (i) upregulated genes, with positive t-statistics, (ii)
downregulated genes, with negative t-statistics, (iii) up- or
Table 1. Human sample characteristics
Type Sexe Age Brain white matter area
cALD Male 6 Frontal
cALD Male 13 Frontal
cALD Male 8 Frontal
cAMN Male 17 Frontal
cAMN Male 39 Frontal
cAMN Male 43 Parietal
cAMN Male 47 Frontal
cAMN Male 28.5 Frontal
cAMN Male 33 Frontal
cAMN Male 48 Parietal
cAMN Male 66.5 Frontal
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expressed regardless of the direction. When the function
gives a signiﬁcant result, it means that at least one of four
tests is signiﬁcant. GOstats package contains a function
called GOHyperG that can be used to ﬁnd GO terms that
may be enriched in a subset of genes. It is based on a hyper-
geometric distribution. We used the ‘phyper’ hypergeometric
distribution function from stats package to determine enriched
KEGG pathways in a subset of genes.
Quantitative real-time PCR
One microgram of RNA was transcribed into cDNA using
Superscript II reverse transcription reagents in a ﬁnal
volume of 25 ml (Invitrogen). A TaqMan RT-PCR was per-
formed within the ABI PRISM 7300HT sequence detection
systemusingtheTaqManUniversalPCRmastermixandthe
standardized primers for mouse Ikbkb (Mm01222247_m1),
Nfkb2 (Mm00479807_m1), Tnfrsf1a (Mm01182929_m1),
Adipor1 (Mm01291334_mH), Sars (Mm00803379_m1),
Gars (Mm00619269_m1), Aars (Mm00507627_m1), Akt2
(Mm00545827_m1), Irs1 (Mm01278327_m1), Irs2 (Mm0
3038438_m1), Ndufs7 (Mm00503957_m1), Sdha (Mm01
352366_m1), Uqcrc1 (Mm00445911_m1), Cox4i1 (Mm01
250094_m1), Rps9 (Mm00850060_s1), Rps27 (Mm00
850051_g1) and Rpl23 (Mm00787512_s1).
Each sample was run in duplicate, and the mean value of the
duplicate was used to calculate the mRNA expression of the
genes of interest which were normalized to that of the refer-
ence control (18S, Hs99999901) using the comparative
(2
2DCt) method, according to the manufacturer’s instructions.
PCR array (TLR signaling pathway and inﬂammatory
cytokines and receptors)
PCR microarray for TLR pathway was performed by using
RT2-Proﬁler PCR Array from SuperArray Bioscience
(Mouse Toll-Like Receptor Signalling Pathway PAMM-018
and Inﬂammatory Cytokines and Receptors PAMM-011). A
96-well plate contains gene-speciﬁc primer sets for 84 relevant
genes for both TLR Signalling Pathway and Inﬂammatory
Cytokines and Receptors, ﬁve housekeeping genes and two
negative controls. After performing thermal cycling, real-time
ampliﬁcation data were analyzed by using ABI Prism 7300HT
software. Gene expression was normalized to internal controls
(housekeeping genes) to determine the fold change in gene ex-
pression between Wt and Abcd1 null mice.
Antibodies
The following antibodies were used for western blots: poly-
clonal phosphoserine 307 IRS1 antibody (07-247) and poly-
clonal IRS1 antibody (06-248) were obtained from
Chemicon International (Temecula, CA, USA). Antibodies
against SAPK/JNK (number 9252), Phospho-SAPK/JNK
(Thr183-Tyr185) (9251), Akt (pan) (11E7) (4685),
phospho-Akt (Ser473) (587F11) (4051), phospho-Akt
(Thr308) (244F9) (4056), phospho p70S6K (Thr389) (9205),
phospho-IKKa-Ser180/IKKb-Ser181 (2681) were obtained
from Cell Signaling (Beverly, MA, USA). Monoclonal
phospho-Tyr (PY20) (sc-508), IkBa (sc-1643), IKKb
(sc-7330) and a-p52 (sc-7386) were purchased from Santa
Cruz Biotechnology. IKKa (OP-133) was purchased from
Oncogen and a-tubulin from Sigma. Goat anti-mouse-HRP
secondary antibody was obtained from Invitrogen (Eugene,
OR, USA).
Tissue extracts and western blot analysis
Spinal cord from control and X-ALD mice were collected,
frozen in liquid nitrogen and stored at 2708C until further
analysis. Fresh frozen spinal cords were homogenized in
5 vol of ice-cold lysis buffer (RIPA buffer: 25 mM Tris–
HCl, pH 6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycho-
late, 0.1% SDS with complete protease inhibitor cocktail
(Roche) and phosphatase inhibitor cocktail (Roche) followed
by sonication. Homogenates were centrifuged at 1000 rpm
×5′ at 48C, and supernatants were collected. Protein concen-
tration was assessed using bicinchoninic acid assay (Pierce,
Rockford, IL, USA). Samples containing 50–75 mgo f
protein in reducing sample buffer were fractionated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis.
Proteins were transferred to Hybond-C nitrocellulose mem-
branes and subjected to western blots with indicated antibodies
followed by quantiﬁcation by a scanning densitometer. Signals
were normalized to loading controls.
Organotypic spinal cord slice culture
The spinal cords from 18-day-old mice were immediately
removed and placed in ice-cold dissecting media (pH 7.15).
Next, the spinal cord was cut into 350-mm thick slices using
a McIlwain tissue chopper to generate the organotypic slice
cultures and placed into a sterile Petri dish with Grey’s
balanced salt solution. Spinal slices were transferred onto
Millicell-CM cultured plate inserts (Millipore, MA, USA).
The inserts were placed into wells of a 6-well plate containing
1.0 ml of medium containing 50% MEM with Earl’s salts and
glutamine, 25% Hanks balanced salt solution and 25% horse
serum supplemented with 20 mM of HEPES acid–salt and
D-glucose (6 mg/ml) (Gibco-BRL). Slices were incubated at
378C for different period of times and media were changed
twice a week (56,57). After 2 weeks of culture, OSCSC
have been treated with C26:0 fatty acid dissolved in ethanol
(22).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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